Please login to the form below

Not currently logged in
Email:
Password:

Extra support for thalidomide survivors

A new compensation package for those affected by thalidomide has been unveiled by health minister, Mike O'Brien

A new compensation package for those affected by pregnancy drug, thalidomide has been unveiled by health minister, Mike O'Brien.

The drug was used between 1958 and 1961 to help control symptoms of morning sickness in expectant mothers. It was later withdrawn in 1961 after babies were born with severe physical disabilities.

Along with news of the compensation, O'Brien also offered an official apology, saying: "The Government wishes to express its deep sympathy for the injury and suffering endured by all those affected."

The scheme itself will be operated by the Thalidomide Trust, who offer support and assistance to the 466 current survivors of thalidomide.

They will be in control of a "£20m, three-year pilot scheme to meet health needs of thalidomide survivors in a more personalised way," according to O'Brien, with funding coming from existing departmental central contingency budgets.

With survivors now approaching 50, O'Brien also reported back on the National Advisory Council to the Thalidomide Trust's concerns about "the continuing and increasing health needs of Thalidomiders as they approach older age."

He said: "This additional funding will help to meet their complex and highly specialised needs, and to reduce further degeneration in their health."

14th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics